Research Director at the CNRS within the Stem Cell and Brain Research Institute (SBRI), Inserm U1208, University of Lyon and Co-Founder, in 2009, of the Joint Laboratory on Neuropathogenesis along with Prof. Chonggang YUAN at East China Normal University (ECNU) in Shanghai, integrated into the Key Laboratory of Brain Functional Genomics at the ECNU in January 2014.
The main objective is the transfer of fundamental discoveries using small antibody mimetics called peptide aptamers, to potential patient benefit in the context of the StemGamE platform.
The present transfer focus: • neurodegenerative diseases - e.g. ALS (Amyotrophic Lateral Sclerosis - Maladie de Charcot) • stimulation of the immune response e.g. for adoptive cell therapy of certain cancers • enhancement of safety of the use of embryonic stem cell-derived cultures for potential therapeutic benefit.
|1989||Raven Press, Ltd., New York. 195-202||Nerve growth factor-sensitive phosphorylations and the action of K-252a on PC12 cells||Koizumi S, Mutoh T, Ryazanov A, Rudkin BB, Guroff G||Trophic Factors and the Nervous System||-|
|1991||3:1-5||To divide or not to divide: When, where and how. Molecular control of the cell cycle and cell differentiation||Rudkin BB||The New Biol||-|
|1988||85(23):8860-4||A human 200-kDa protein binds selectively to DNA fragments containing G.T mismatches||Jiricny J, Hughes M, Corman N, Rudkin BB||Proc Natl Acad Sci U S A||-|
|2000||90:113-125||Sensory neurons respond to long-lasting inflammatory pain by directing NGF receptors to their central terminals and enhancing their projection field in deep layers of the dorsal horn||Pezet S, Onténiente, B, Jullien, J, Junier MP, Grannec G, Rudkin BB, Calvino B||Pain||-|
|1997||14(3):265-75||Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations||Rossel M, Pasini A, Chappuis S, Geneste O, Fournier L, Schuffenecker I, Takahashi M, van Grunsven LA, Urdiales JL, Rudkin BB, Lenoir GM, Billaud M||Oncogene||-|
|1998||17(13):1663-72||Human primitive neuroectodermal tumour cells behave as multipotent neural precursors in response to FGF2||Derrington EA, Dufay N, Rudkin BB, Belin MF||Oncogene||-|
|1999||18(18):2872-82||Cooperation of Sp1 and p300 in the induction of the CDK inhibitor p21WAF1/CIP1 during NGF-mediated neuronal differentiation||Billon N, Carlisi D, Datto MB, van Grunsven LA, Watt A, Wang XF, Rudkin BB||Oncogene||-|
|1998||16(7):825-32||Specific TrkA survival signals interfere with different apoptotic pathways||Ulrich E, Duwel A, Kauffmann-Zeh A, Gilbert C, Lyon D, Rudkin BB, Evan G, Martin-Zanca D||Oncogene||-|
|1997||15(4):393-402||Oncogenic activation of RET by two distinct FMTC mutations affecting the tyrosine kinase domain||Pasini A, Geneste O, Legrand P, Schlumberger M, Rossel M, Fournier L, Rudkin BB, Schuffenecker I, Lenoir GM, Billaud M||Oncogene||-|
|1996||12(4):855-62||Nerve growth factor-induced accumulation of PC12 cells expressing cyclin D1: evidence for a G1 phase block||van Grunsven LA, Thomas A, Urdiales JL, Machenaud S, Choler P, Durand I, Rudkin BB||Oncogene||-|